Podcasts about drug pricing

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the significant events of 2025, a year marked by pivotal scientific breakthroughs, regulatory changes, and industry trends that have reshaped drug development and patient care.One of the standout advancements was Novo Nordisk gaining FDA approval for an oral version of Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist for obesity management. This marks a notable shift in treatment accessibility, as it provides an easier alternative to injectables for those managing weight and cardiovascular risks. This development could significantly enhance patient adherence and broaden access to this critical therapy.However, not all news was positive. Pfizer faced a challenging situation when a patient death occurred in the extension of their Hympavzi hemophilia study. Such incidents highlight the intrinsic risks of clinical trials, especially within gene therapy realms where safety monitoring is paramount. These events remind us of the delicate balance between innovation and patient safety in advanced biologic therapies.In legal news, Johnson & Johnson was ordered by a Baltimore jury to pay $1.56 billion in a talc-related cancer case. This ruling underscores heightened scrutiny on product safety and consumer protection within the pharmaceutical industry, potentially influencing future litigation and regulatory measures.Clinical trial outcomes also presented mixed results. Neurocrine Biosciences' Ingrezza did not meet efficacy endpoints in its phase 3 trial for cerebral palsy-related dyskinesia. Although it is approved for other movement disorders, this setback reflects the complexities involved in expanding drug indications. Such challenges highlight ongoing hurdles in translating preclinical successes into clinical realities.Despite geopolitical tensions, particularly between China and the U.S., Chinese biotech firms thrived, maintaining robust deal activity. China's continued growth as an innovation hub is driven by strategic investments and collaborations that bolster global drug development efforts, underscoring its increasing influence in life sciences.Regulatory landscapes also shifted with proposals from the Center for Medicare & Medicaid Innovation to align U.S. drug prices with international rates under Medicare Parts B and D. These proposed models could significantly impact pricing strategies and market dynamics within the U.S., requiring pharmaceutical companies to adapt while ensuring equitable access to medications.Ethical challenges surfaced as six individuals were charged with insider trading involving biotech stocks. Such incidents highlight the necessity for stringent ethical standards and regulatory oversight to maintain investor confidence and market integrity.Meanwhile, AstraZeneca's extended partnership with Niowave for actinium-225 supply reflects an interest in radiopharmaceuticals as targeted cancer therapies. This collaboration highlights the potential of radiopharmaceuticals in oncology, opening promising avenues for precision medicine approaches.As 2025 closes, it's clear that this year has been one of both triumphs and trials for the pharmaceutical and biotech industries. Scientific innovations like Novo Nordisk's oral GLP-1 receptor agonist offer new hope for patients, yet challenges such as clinical trial setbacks and legal battles indicate ongoing hurdles in drug development and commercialization. These developments will likely influence industry strategies and regulatory policies as we advance into 2026.The sustained momentum of China's biotech industry amid global trade tensions remains notable. This trend reflects China's strategic investments in biotech capabilities and its growing role in global markets despite geopolitical frictions.In clinical research, Hope BioscienceSupport the show

Trump's drug pricing deals fail patients, media enables plutocratic lies, and Congressman Al Green's affirmation reinforces why truth-telling with solutions still matters.Subscribe to our Newsletter:https://politicsdoneright.com/newsletterPurchase our Books: As I See It: https://amzn.to/3XpvW5o How To Make AmericaUtopia: https://amzn.to/3VKVFnG It's Worth It: https://amzn.to/3VFByXP Lose Weight And BeFit Now: https://amzn.to/3xiQK3K Tribulations of anAfro-Latino Caribbean man: https://amzn.to/4c09rbE

Thank you Steven Rosenzweig, Lana Foley, Donna DeMunbrun, Anne Collins, IOLET ELAINE AMBROSE, and many others for tuning into my live video! Join me for my next live video in the app.* Trump's 9 New Prescription Drug Deals ‘No Substitute' for Systemic Reform: “Patients are overwhelmingly calling on Congress to do more to lower prescription drug prices by holding Big Pharma accountable and addressing the … To hear more, visit egberto.substack.com

The pharmaceutical industry has seen major legal and policy changes in recent years, from the Inflation Reduction Act to the Trump administration's aggressive pricing policies. In this episode of Connected With Latham, Mike Domanico, a pharmaceutical industry veteran with experience in Big 4, brand drugs, biosimilars, and generics, and most recently Vice President of Revenue Finance, joins Washington, D.C. partner Chris Schott and associate Danny Machado to discuss how organizations can best respond to the changing environment. As Mike explains, think of meeting the challenge as a loop that connects the business, compliance, and legal in a cross-functional collaboration. Also check out our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in your inbox.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200

This episode announces the launch of CMS's ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) model - a groundbreaking payment innovation that enables technology-enabled care organizations to treat Medicare fee-for-service patients with chronic conditions through outcome-aligned payments rather than traditional fee-for-service. Abe Sutton (Director of CMMI) and Jacob Shiff (Chief AI & Technology Officer at CMMI) explain how the model addresses a fundamental gap in healthcare: while commercial and Medicare Advantage patients have access to digital therapeutics and technology-enabled chronic disease management, original Medicare beneficiaries have been left behind. ACCESS changes this by paying providers monthly fees for managing conditions like diabetes, hypertension, obesity, behavioral health issues, and musculoskeletal pain - but only when patients achieve measurable clinical improvements. The model is designed to be deflationary rather than inflationary, encourages innovation by simplifying go-to-market for digital health startups, integrates with existing risk-bearing models like ACOs, and represents a broader CMMI strategy to shift from activity-based to outcome-based payments while leveraging new AI capabilities to democratize high-quality care. (0:00) Intro(0:57) The ACCESS Model: Advancing Chronic Care(4:35) Outcome-Aligned Payments and Technology(7:40) Encouraging Innovation and Investment(09:23) Practical Implementation and Examples(24:28) Evaluating Success and Future Goals(26:18) Connecting the Dots: Broader CMMI Initiatives(28:40) Generous and Its Impact on Drug Pricing(30:11) Challenges and Benefits of Prior Authorization(35:19) The Role of Technology in Healthcare(37:59) AI and Technology-Enabled Care(40:26) Reflections on Value-Based Care Models(43:51) Encouraging Competition in the Healthcare Market(48:24) Quickfire Out-Of-Pocket: https://www.outofpocket.health/

I was out drinking martinis with Cora Opsahl, director of 32BJ Health Fund, and Cora said, "Look, most plan sponsors' biggest expense is health system spend, hospital spend." I know this is an unexpected start to an episode about pharmaceutical pricing and value featuring Sarah Emond, CEO of ICER (Institute for Clinical and Economic Review). But yeah, 50% of most plan sponsors' spend these days goes to health systems. Fifty percent! One half! For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. So, if a patient who is adherent to a drug and that drug keeps that patient out of the hospital, why do I want to make a patient have excessive skin in the game to get that drug, which everybody knows at this point this "skin in the game" can cause said patient to not be adherent in many cases, cost being a very big reason patients give for not taking medications as prescribed. So then we have this not adherent patient who winds up in the hospital, via the ER often enough. The core issue here that surfaced, bottom line—and I'm not sure if this was in spite of the martinis or as a result of them—but while hospital spend is the largest health expense, high-value drugs that prevent hospitalization often face patient cost sharing and access restrictions, which leads to poor patient adherence and ultimately higher system cost potentially. So then Cora and I spent the next half hour debating when the statement is empirically true and when it's not. And you know what it all boils down to? What's the value of the drug? Do we even know what that means to start? But if it's determined that the drug is relatively high value, then the plan desperately should want to do everything possible to keep that patient on that medication, and cost sharing is a huge barrier to adherence. Today, as I said, I'm speaking with Sarah Emond, CEO over at ICER, and we get into all of this in the conversation that follows. In fact, most of the conversation that follows explores the tensions that exist in the current way that we sell and buy pharmaceutical products. I'm just gonna sum up these tensions in a list here at the top of this show. There's six of them that Sarah Emond and I discussed today by my counting, and each of these we explore in some depth. So, here's the list. Tension 1: The value of any given drug (in other words, what is the fair price for that drug considering the health gains that it delivers) versus the total cost to the plan for the total population taking that drug. GLP-1s have entered the chat. GLP-1s (by ICER's analysis, at least) are super high-value drugs that also can bankrupt plans due to the number of folks who may benefit from taking the drug. Definitely a tense tension to kick off our list here. Tension 2: The list or net price of a drug versus patient access and affordability. Again, this can be tense in an area of much misalignment. You can have a great well-priced drug with huge patient affordability and access challenges because drug net price and coinsurance amounts often have nothing to do with each other. Tension 3: Lifetime value of a drug versus a 3-, 2.5-year, whatever time horizon that many plan sponsor actuaries use in their value assessment. We discussed this today, but there's a Summer Short (SUMS7) on actuarial value horizons with Keith Passwater and JR Clark if you wanna dig in on this further. Tension 4: The tension between the societal value of a drug or even the patient's perceived value of a drug versus what an employer plan sponsor might perceive as the value. What is the formula used to determine value? What's in and what's out? So, that's a bigger conversation just beyond the time horizon for what's included in this calculation. Tension 5: Exacerbating the what's included in the value contemplation beyond just what you include in there is the tension between what is hypothetically of value and what is possible to measure. If you have pharma datasets and medical datasets separate in silos, who knows how many hospital readmissions were prevented by whatever drug? And how much presenteeism or absenteeism exists. I mean, it is an outlier, again, if anyone even knows the net price they paid for a drug, just to level set context here. Tension 6: Lowering financial barriers for patients to take drugs that are of value versus status quo goals and incentives. Like, for example, PBMs (pharmacy benefit managers) are often told that their goal is to reduce drug spend. Okay … so, how do I do that? Oh, reduce access either by prior auths or delay tactics or really high coinsurance, which is gonna reduce adherence by design. And it's someone else's problem—if I'm just thinking like a status quo PBM—if medical spend goes up, right? So, that's our last and not insignificant tension. And look, who comes out the loser in all of these tensions when they get tense? Patients. Not pricing based on value and not buying and setting up cost sharing based on value punishes patients and also plan sponsors or any other ultimate purchaser in the long term, given that the plan is but a population of patients if you start thinking about it in that context. Here is Sarah's advice in a nutshell: Pharma, sell. Pick your price based on something other than market power. And some pharma companies are actually dipping their toe into these waters and doing it. But then PBMs and plan sponsors have to hold up their end of the bargain here and buy drugs based on their value, not just the size of their rebates or some other discounting promise. And then we gotta continue the through line through to member affordability and access. High-value drugs should get preferred. So, right, do a high-value formulary. Listen to the show with Nina Lathia, RPh, MSc, PhD (EP426) on high-value formularies and then listen (after you're done with that one) to episode 435 with Dan Mendelson entitled "Optimized Pharmacy Benefits Are Required if You Want to Do or Buy Value-Based Care." Also, as I said, GLP-1s come up in this conversation, so … yeah, buckle up. One last thing, besides my normal thank you to Aventria Health Group for sponsoring this episode, I am so pleased to thank Payerset for donating to help Relentless Health Value stay on the air. Payerset is a price transparency company with a mission to create fair and equitable healthcare for everyone. Love that. Payerset empowers healthcare organizations, employers, and patients with the most complete set of healthcare price transparency data. They benchmark every negotiated rate and claim and delivering the actionable insights needed for smarter contract negotiations and a more transparent healthcare system. As I have said several times today, my conversation is with Sarah Emond, CEO of ICER. Also mentioned in this episode are Institute for Clinical and Economic Review (ICER); Cora Opsahl; 32 BJ Health Fund; Keith Passwater; JR Clark; Nina Lathia, RPh, MSc, PhD; Dan Mendelson; Aventria Health Group; Payerset; Antonio Ciaccia; Elizabeth Mitchell; Purchaser Business Group on Health (PBGH); Shane Cerone; Sam Flanders, MD; Mark Cuban; Morgan Health; and Tom Nash. For a list of healthcare industry acronyms and terms that may be unfamiliar to you, click here. You can learn more at ICER.org and follow Sarah on LinkedIn.   Sarah K. Emond, MPP, is president and chief executive officer of the Institute for Clinical and Economic Review (ICER), a leading nonprofit health policy research organization, with 25 years of experience in the business and policy of healthcare. She joined ICER in 2009 as its first chief operating officer and third employee and has worked to grow the organization's approach, scope, and impact over the years. Prior to joining ICER, Sarah spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company and several years with a healthcare communications firm. Sarah began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston. A graduate of the Heller School for Social Policy and Management at Brandeis University, Sarah holds a Master of Public Policy degree with a concentration in health policy. Sarah also received a bachelor's degree in biological sciences from Smith College. Sarah speaks frequently at national conferences on the topics of prescription drug pricing policy, comparative effectiveness research, and value-based healthcare.   08:18 Why list prices are a lie. 10:59 How does the rebate model sometimes get in the way of paying for value? 12:50 Bonus clip with Sarah Emond. 13:14 EP491 with Elizabeth Mitchell. 13:20 EP490 and EP492 with Shane Cerone and Sam Flanders, MD. 14:37 The tension that is created between affordability and adherence. 15:03 When cost sharing makes sense in pharmaceutical drug pricing. 17:26 INBW42 with Stacey on moral hazard. 18:53 How GLP-1s are "wildly cost effective." 21:32 Why the sticker shock on cost-effective drugs is a failure in the system for paying for value. 22:38 ICER's report on GLP-1s. 26:59 EP385 with Dan Mendelson. 28:57 How employers and payers can have a value assessment approach and a health insurance system that allows access to cost-effective drugs. 29:48 How cost-effective prices are calculated. 31:55 One of the core value underpinnings for value assessment of drugs. 34:54 Why manufacturers and pharmacy benefit managers should work together more by referencing something like an ICER report. 36:55 EP426 with Nina Lathia, RPh, MSc, PhD. 38:21 "We can make different choices."   You can learn more at ICER.org and follow Sarah on LinkedIn.   @sarahkemond discusses #pharmaceutical #drugpricing on our #healthcarepodcast. #healthcare #podcast #financialhealth #patientoutcomes #primarycare #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Stacey Richter (INBW43), Olivia Ross (Take Two: EP240), John Quinn, Dr Sam Flanders and Shane Cerone (EP492), Elizabeth Mitchell (EP491), Shane Cerone and Dr Sam Flanders (Part 1), Dan Greenleaf (Part 2), Dan Greenleaf (Part 1), Mark Cuban and Cora Opsahl

President Trump claims that most-favored-nation pharmaceutical pricing is the ''greatest thing ever'' for patient affordability... but critics of the strategy, including the US Chamber of Commerce, are not convinced (at 14:15) --- Around Town: Cops and Kids will Go Shopping this weekend... it is the signature program of the Fort Findlay FOP Lodge 20 Foundation (at 22:58) --- Remember, Honor, Teach... Organizers are still looking for last-minute donations and volunteer manpower to make the Wreaths Across America program happen locally (at 32:04)

Government pricing assessments are an important tool to help pharmaceutical manufacturers review their government price reporting function. They can also help uncovering strategic benefits and opportunities. In this episode of Connected With Latham, Eliza Biedziak, Managing Director at Ernst & Young LLP, joins Washington, D.C.  partner Chris Schott and associate Danny Machado to explore how these assessments are conducted, the compliance benefits they offer, and the strategic insights they can provide. Also check out our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in your inbox.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200

See omnystudio.com/listener for privacy information.

The Friday Five for November 14, 2025: iPhone Pocket Brings Back… Pockets. CMS Rural Health Transformation Program Government Shutdown Update Most-Favored Nation Drug Pricing CMS GENEROUS Model   Get Connected:

In this episode of Disruption/Interruption, host KJ interviews Mark Mincy, Chief Commercial Officer at US RX Care, about the hidden complexities and conflicts of interest in the pharmacy benefits industry. Mark shares how his company is disrupting the status quo by demanding transparency, eliminating conflicts, and helping employers reclaim millions in savings. The conversation uncovers the tangled web of PBMs, rebates, and the urgent need for legislative and technological change. Key Takeaways: The PBM System is Riddled with Conflicts of Interest [2:34]Mark explains how pharmacy benefit managers (PBMs) and consultants often act in their own financial interest, not the employer’s or patient’s, leading to inflated drug costs. Rebates and Purchasing Contributions Inflate Drug Prices [8:59]The system of rebates and retrospective payments to PBMs can account for up to 80% of a drug’s cost, forcing manufacturers to raise prices and employers to pay more. Transparency and Fiduciary Duty are Essential for Reform [21:37]Mark’s company, US RX Care, operates with complete transparency, passes back all rebates, and offers per-member-per-month guarantees to eliminate guesswork and conflicts. Employers and Consumers Can Take Action [33:34]Mark recommends joining healthcare purchaser coalitions, hiring ERISA attorneys, and demanding non-conflicted consultants to protect interests and drive industry change. Quote of the Show [31:27]:"Everything's intertwined. You want to move and do the right thing. These employers are between a rock and a hard place, so I do think some legislative action needs to occur." – Mark Mincy Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Mark Mincy: LinkedIn: http://www.linkedin.com/in/mark-mincy-a185497 Company Website: https://us-rxcare.com How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

The White House has struck a deal with two more drugmakers: Eli Lilly and Novo Nordisk. Centers for Medicare and Medicaid Services administrator Dr. Mehmet Oz discusses the administration's plan to make GLP-1s more affordable for Americans. Tesla shareholders voted to approve Elon Musk's $1 trillion pay package, as long as he reaches their lofty goals for the company. Musk biographer Walter Isaacson discusses the plan of milestones and Musk's history of exceeding investor expectations. Plus, U.S. airlines are beginning to cancel flights to manage shutdown-strained staffing of air traffic controllers, and Warren Buffett issued a warning on AI.  Dr. Mehmet Oz - 21:43Walter Isaacson - 38:56 In this episode:Dr. Mehmet Oz, @DrOzJoe Kernen, @JoeSquawk Andrew Ross Sorkin, @andrewrsorkinKatie Kramer, @Kramer_Katie Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Stock market update for November 5, 2025.Follow us on Instagram ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@therundowndaily⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠This video is for informational purposes only and reflects the views of the host and guest, not Public Holdings or its subsidiaries. Mentions of assets are not recommendations. Investing involves risk, including loss. Past performance does not guarantee future results. For full disclosures, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Public.com/disclosures⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

The new FDA Commissioner's National Priority Voucher (CNPV) pilot program promises to reduce recipients' application review times from 10-12 months to just 1-2 months. As part of the Trump administration's push for most favored nation (MFN) pricing, drug affordability is one criterion for vouchers, marking FDA's entry into the drug pricing fray. In this episode of Connected With Latham, Washington, D.C. partner Chris Schott and counsel Monica Groat explore the voucher awards in detail and discuss how the accelerated review period might affect launch strategies, whether companies with no voucher will be disadvantaged, and potential risks and concerns. Also check out our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in your inbox.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200

Subscribe to UnitedHealthcare's Community & State newsletter.Health Affairs' Jeff Byers welcomes Stacie Dusetzina of Vanderbilt University Medical Center and David Simon of the University of Connecticut back to the pod to the current state of drug prices, how proposed tariffs may impact the pharmaceutical industry, that Pfizer deal, what consumers can expect if tariffs are added to prescription drugs, what exactly TrumpRx is, and more.Become an Insider today to get access to our third trend report focusing on the influence of private equity in health care.Related Articles:Trump admin readies 'imminent' probe into other nations' drug pricing, raising new tariff threat: FT (FiercePharma)President Trump's Executive Orders On Prescription Drug Prices: What The Evidence Says (Health Affairs Forefront) Subscribe to UnitedHealthcare's Community & State newsletter.

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith and Editor-in-Chief Nielsen Hobbs discuss the reasons US Food and Drug Administration Commissioner Martin Makary could have helped negotiate the Most Favored Nation drug pricing deal with Astra Zeneca (:30) and the deal's potential impact on the 340B program (16:35). They also consider the Justice Department's alternative interpretation of off-label promotion regulations and the effect on the scientific exchange of information about drugs (19:16). More On These Topics From The Pink Sheet US FDA Commissioner's Involvement In AstraZeneca Pricing Deal Raises Ethical, Legal Questions: https://insights.citeline.com/pink-sheet/market-access/pricing-debate/us-fda-commissioners-involvement-in-astrazeneca-pricing-deal-raises-ethical-legal-questions-IJV4LMTDA5E65KCOFQUQM76GCA/ EMD Serono IVF Candidate Among First US FDA Priority Voucher Recipients As Part Of MFN Deal: https://insights.citeline.com/pink-sheet/market-access/pricing-debate/emd-serono-ivf-candidate-among-first-us-fda-priority-voucher-recipients-as-part-of-mfn-deal-LKHA6VRTKRE6DJERGNCWCGMBF4/ Manufacturer Most Favored Nation Deals: How They Could Be Protected From 340B: https://insights.citeline.com/pink-sheet/market-access/pricing-debate/manufacturer-most-favored-nation-deals-how-they-could-be-protected-from-340b-FALSG7GHM5GQBFN3I5SPERJIYU/ Off-Label Promotion: DOJ May Take New Look At Scientific Information Exchange: https://insights.citeline.com/pink-sheet/legalandip/litigation/off-label-promotion-doj-may-take-new-look-at-scientific-information-exchange-R62PQJFQTRBCVGCZE57GWM3Q3Q/

A look at how Oracle started to win mega-deals over its competitors. Now Inking an agreement with Meta. Looking to further diversify its customer base. Then stocks in the weight loss industry falling after President Trump says prices will soon be coming down. One of the street's top health care strategists give his outlook. Plus, Apple striking a deal for the U.S. Formula 1 rights. A look at its live event strategy and what it means for F1 with the CEO of the Cadillac F1 team. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This episode features Paige Twenter, Assistant Editor at Becker's Hospital Review. Twenter highlights three major healthcare stories shaping the industry today, including new H-1B visa fees and their impact on the workforce, Most Favored Nation drug pricing deals, and evolving vaccine mandates and access across the U.S.

Send us a textSchedule an Rx AssessmentSubscribe to Master The MarginAs a pharmacy owner, it often feels like you're fighting battles against systems designed to work against you.Few battles loom larger than the fight against Pharmacy Benefit Managers whose opaque practices have chipped away at margins, patient trust, and sustainability for independents.In this episode, we have two very special guests on the front lines of PBM reform: Dared Price, President of OreadRx and Price Pharmacies and Mark Cuban, legendary entrepreneur and co-founder of Cost Plus Drugs.Scotty Sykes, CPA, CFP®, Bonnie Bond, CPA, MBA, and Austin Murray sit down with Mark Cuban and Dared Price to explore how transparent models are reshaping the future of drug pricing and pharmacy benefit management.We cover:The real impact of spread pricing, rebates, and hidden contracts on pharmacy ownersHow Cost Plus Drugs is cutting out middlemen to bring transparency to patients and pharmaciesWhy OreadRx's transparent PBM model could change the game for independentsWhat a fair reimbursement ecosystem might look like and how owners can prepareAnd more!Stay connected with Dared Price, OreadRx, Mark Cuban and Cost Plus Drugs:  Dared Price LinkedInOreadRx WebsiteOreadRx FacebookCost Plus Drugs WebsiteCost Plus Drugs LinkedInCost Plus Drugs FacebookStay connected with us on social mediaFacebookTwitter (X)LinkedInInstagramScotty Sykes – CPA, CFP LinkedInScotty Sykes – CPA, CFP TwitterBonnie Bond - CPA, MBA LinkedInMore resources about this topic:Podcast - Pharmacy's Never Ending Story: PBM Reform Act and Medicare Drug Pricing ChangesPodcast - Pharmacy Ownership Through TimePodcast – The State of PBM Reform

Amy Kelbick and Simeon Niles join Julia Grabo to discuss the implementation of President Trump's most-favored nation drug pricing executive order, including how manufacturers are responding and possible next steps.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Zenas has made a $2 billion bet on autoimmune diseases with Chinese firm InnoCare, focusing on the development of orelabrutinib for multiple sclerosis. Former FDA director Peter Marks has joined Eli Lilly, marking the company's continued push in China. Sanofi's advancements in radiopharma, Boehringer Ingelheim's breakthrough in idiopathic pulmonary fibrosis, and Takeda's exit from cell therapy are also top stories. Cytiva filtration is highlighted as a solution for maintaining product integrity in biopharma.Biospace profiles the five most powerful women leading smaller biopharmaceutical companies, as the industry sees a shift with the departure of GSK CEO Emma Walmsley. A survey by CRB reveals that most life sciences companies are not planning new investments after tariffs, with big pharma taking the lead in manufacturing initiatives. Drug pricing criticism often overlooks the dynamic nature of drug pricing over time. Takeda's journey in building a cell therapy portfolio, only to ultimately walk away, is explored. Pfizer wins the bid for Metsera, Amgen offers Repatha at a discounted rate, and Roche acquires Akero for $3.5 billion. Biospace also honors 40 under 40 winners making an impact in the industry.Peter Marks, former director of the FDA's Center for Biologics Evaluation and Research, has taken on a new role as Senior Vice President for molecule discovery and the head of infectious diseases at Eli Lilly. Marks' controversial exit from the FDA led to his hiring by Lilly, following in the footsteps of another former FDA official, Rachael Anatol. Marks confirmed his new role to Stat News and began his first day at Lilly Research Laboratories on Monday.Support the show

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith, and senior editors Sue Sutter and Cathy Kelly consider the impact of the government shutdown on the US Food and Drug Administration, as well as industry (:21), and discuss the future of drug pricing after Pfizer completes its deal with the White House to embrace its Most Favored Nation plan (10:29). More On These Topics From The Pink Sheet Shutdown Approaches: US FDA Would Retain Most Of Recently Trimmed Staff: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/shutdown-approaches-us-fda-would-retain-most-of-recently-trimmed-staff-DTVAHLBI5VGZBPHD76TLNDIBGU/ Shutdown Day One: US FDA Hiring, MFN Demos Delayed?: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/shutdown-day-one-us-fda-hiring-mfn-demos-delayed-7LGCITF2WVCJNEVUTWZV5MOZSE/ Closing The Gap? Pfizer Will Set Same US, Foreign Launch Prices In MFN Deal: https://insights.citeline.com/pink-sheet/market-access/pricing-debate/closing-the-gap-pfizer-will-set-same-us-foreign-launch-prices-in-mfn-deal-ZRSNU56KTFGRBBX4Y5OJKLFV6Y/ Questions Persist About How Pfizer's US Agreement Lowers Prices: https://insights.citeline.com/pink-sheet/market-access/pricing-debate/questions-persist-about-how-pfizers-us-agreement-lowers-prices-T2TEWMKVMVHGJHPXDKIFDF2GWA/

Stakeholders from across the healthcare industry — from manufacturers and consultants to outside counsel and government officials — recently convened in Chicago for the Medicaid Drug Rebate Program Summit 2025. In this episode of Connected With Latham, Washington, D.C. partner Chris Schott, counsel Nicole Liffrig Molife, and associate Danny Machado share impressions and key takeaways from the conference, including action items like readying litigation support to address likely future challenges. Also check out our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in your inbox.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Pfizer's recent deal with the Trump administration regarding drug pricing has sparked concerns about access to medications, particularly with a focus on commitments to manufacturing in the U.S. and tariff exemptions. The ongoing U.S. government shutdown has had a direct impact on the FDA's ability to accept new drug applications, creating challenges for the industry. Fortress and Sentynl faced hurdles in securing FDA approval due to manufacturing issues, while the third quarter of the year witnessed a flurry of significant biopharma acquisitions.In response to their agreement with the government, Pfizer is offering drugs at a discount, showcasing their commitment to affordable healthcare. Amidst these developments, there is a growing need to redefine the future of UK biotech and explore advancements in medicine, such as Novartis' recent approval of an oral BTK inhibitor for chronic hives.The biopharma industry saw a surge in mergers and acquisitions during the third quarter, with some of the largest deals in recent history taking place. Big pharma companies have substantial financial resources available for M&A transactions, with traditionally conservative companies leading the way. However, a small percentage of life sciences M&A milestones have been paid since 2008, indicating that many deals are still pending.Conversations between the UK government and the pharma industry have hit roadblocks, leading to a slowdown in investment. Additionally, Promoveo Health, a prominent contract sales organization, offers top-tier field sales talent at competitive rates. In other news, GSK's CEO Emma Walmsley steps down after nearly a decade at the helm.Despite these shifts in the industry landscape, it is crucial to stay informed about upcoming webinars and events that offer valuable insights into the world of biopharma.Support the show

As the U.S. government has entered a shutdown, Shane drops by to explain the scope of impact, along with next steps with respect to negotiations. Plus, thoughts on yesterday's Oval Office announcement related to drug pricing. Featured is Shane Lieberman, Senior Governmental Affairs Advisors, Government Affairs US. Host: Daniel Cassidy

As the U.S. government has entered a shutdown, Shane drops by to explain the scope of impact, along with next steps with respect to negotiations. Plus, thoughts on yesterday's Oval Office announcement related to drug pricing. Featured is Shane Lieberman, Senior Governmental Affairs Advisors, Government Affairs US. Host: Daniel Cassidy

Genmab's $8 billion acquisition of multispecifics company Merus is the Danish biotech's largest step toward marketing its own pipeline. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the evolution of Genmab, which, for many years, relied on a partnership model that delivered blockbuster revenues but now is making a change as a patent cliff looms.The analysts also assess the tenure of Emma Walmsley the longtime CEO of GSK, and what's next for the U.K. pharma under incoming CEO Luke Miels. Turning to the U.S., Washington Editor Steve Usdin discusses President Donald Trump's looming tariff threat on imports of branded drugs, which Usdin says would hurt small biotechs the most. Usdin also analyzes the response of multinational pharmaceutical companies to the president's demand that they make “most favored nation” price concessions, now that Monday's deadline has passed. This episode of BioCentury This Week is sponsored by IQVIA Biotech.View full story: https://www.biocentury.com/article/657131#biotech #pharma #deals #FGF21 #MASH #Interleukin5 #asthma #PhRMA #PBM #tarriff #MFN00:01 - Sponsor Message: IQVIA Biotech02:26 - Genmab's Merus Buy09:43 - CEO Switch at GSK17:22 - Trump Tariff Threat21:17 - MFN Drug PricingTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Countdown to shut down. Washington, D.C. is on alert with less than 48 hours to make a deal ahead of a high-profile Oval Office face-to-face today. Plus, investors are watching from the sidelines, gauging the potential market impact with stocks near record highs. Futures are higher. And later, President Trump keeps the pressure on pharma, with new tariffs coming on the back of a critical deadline today. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A takeout that could be worth as much as $7.3 billion has Pfizer back in the obesity drug development race. On the latest BioCentury This Week podcast, BioCentury's analysts discuss Pfizer's acquisition of Metsera and its obesity assets. Plus: Editor in Chief Simone Fishburn gives a recap of BioCentury's Grand Rounds — Europe meeting, which included a fireside chat with Patrick Vallance on the state of the life sciences ecosystem in the country. The BioCentury analysts also assess the state of hot-button policy issues in Washington, such as drug pricing and China. Finally, they analyze the state of play among therapies for narcolepsy on the heels of the World Sleep Congress in Singapore. Check out BIO Chairman Fritz Bittenbender's conversation with BioCentury Washington Editor Steve Usdin on BioCentury This Week's sister podcast, The BioCentury Show. This episode of BioCentury This Week is sponsored by IQVIA Biotech.View full story: https://www.biocentury.com/article/657065 #ObesityDrugs #PharmaDeals #BiotechDeals #MergersAndAcquisitions #DrugDevelopment #Narcolepsy00:01 - Sponsor Message: IQVIA Biotech03:46 - Pfizer's Obesity M&A14:54 - U.K. in Focus28:20 - U.S. Drug Pricing, China Policy40:07 - Narcolepsy PipelineTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In Donald Trump's first presidential term, he spoke a lot about "Most Favoured Nations" pricing for pharmaceuticals - that is, bringing the prices that Americans pay for drugs in line with prices paid around the world. In his first term, all that talk didn't amount to much. But this time around the pharma industry is taking the President much more seriously.   In today's pharmaphorum podcast, host Jonah Comstock speaks with Alice Valder Curran, a partner at Hogan Lovells and our go-to expert on US policy in pharma, for an update on what's happening right now with Most Favoured Nations drug pricing.  Curran brings us up to speed on what's happened with the President's Executive Order and the industry response so far, then she and Comstock break down what was in the recent letters sent by the administration to major pharma companies and subsequently posted on Truth Social by the President.  They talk about the short-term and long-term impacts of the policy, to what extent it's likely to come to fruition, and to what extent the industry has already begun to change its behaviour in response. Check out the full episode below to learn more about what could be the most impactful US policy change for pharma's bottom line in decades. 

In this eye-opening episode, Dr. Lindsey Elmore exposes the chaos unfolding in the UK as Mounjaro (weight loss/diabetes medication) prices skyrocket 170% overnight—jumping from £92 to £330 per month. Discover how Eli Lilly's "European price matching" triggered panic buying, crashed pharmacy websites, and left patients spending over £1,000 to stockpile medications. Lindsey examines the real-world impact, even in the U.S.: supply shortages, hoarding behaviors, and the unfair advantage given to those who can afford to bulk-buy versus patients with genuine medical needs. A must-listen for understanding how arbitrary pharmaceutical pricing decisions affect real people's access to life-sustaining medications.Main Topic Introduction00:00-00:30: Discussion focuses on Mounjaro (weight loss/diabetes medication) pricing crisis in the UKThe Price Hike00:37-01:13: Massive 170% price increase starting September 1st, 2025Current price: £92/monthNew price: £330/month (up from planned £122/month)01:25-01:41: Eli Lilly justifies increase as "adjusting prices to match the rest of Europe"Pharmacy Response00:37 & 01:41-02:01: UK's largest online pharmacy "Pharmacy2U" freezes prices, then stops sales entirelyPanic Buying Crisis02:09-02:34: Patients stockpiling medications before price hikes02:22: Pharmacies offering 3, 6, or 9-month bundles02:44-02:59: Real examples: patients buying 7-8 pens, spending over £1,000 in panic purchases04:35: Pharmacy websites crashing from demandSupply Chain Impact02:59-03:24: Hoarding strains supply chains and prevents access for patients who truly need the medication03:24-03:44: Medical experts urge against hoarding injectable medications at homeCore Issues Identified03:51-04:12: Access and fairness concerns - distinguishing between medical necessity vs. cosmetic use05:37-05:57: Drug prices change "for no reason at all" with no patient input06:08-06:27: Need to prioritize patients who medically need medications over those who can afford to stockpileSolutions Proposed04:59-05:27: Work with legislators through existing Inflation Reduction Act framework06:27-06:55: Legislative action needed to control "absurd" arbitrary drug pricing, especially for life-sustaining medicationsEpisode Conclusion07:06-07:14: Show closing: encouraging wise health decisionsBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-lindsey-elmore-show--5952903/support.

This week on the podcast, Heather and Matthew are joined by Gil Roth, President of the Pharma & Biopharma Outsourcing Association (PBOA), which represents the regulatory, legislative, and general business interests of Contract Development and Manufacturing Organizations (CDMOs) in the bio/pharma space. Gil shares how CDMOs are navigating regulatory uncertainty, the potential impact of tariffs on drug pricing and supply chains, and what recent executive orders could mean for innovation and access to care. Tune in now!

Join our co-hosts Todd Eury and Greg Reybold in this exclusive interview with Conor Sheehey, who most recently served as senior health policy advisor to U.S. Senate Finance Committee Chair Mike Crapo (R-ID). In this role, he advised the Committee on a range of health care policy issues, including prescription drug pricing, telehealth, AI, provider coverage and reimbursement, fraud and abuse, medical devices, and Medicare Parts B and D. Sheehey led several bipartisan legislative efforts, including the development of comprehensive PBM reforms and bipartisan proposals on clinician payment reform and drug shortages.

How can healthcare investment banking put patients—not just profits—at the center of biotech deals? In this episode, host James Zanewicz, JD, LLM, RTTP, speaks with Sam Libby, President and Managing Director of TCB Capital Advisors. Drawing from more than $20 billion in transactions across therapeutics, diagnostics, and digital health, Sam explains how TCB's unique advisory model partners with companies before and after deals close. From growing up with therapist parents to founding a merchant bank, Sam shares how personal values and professional experience can come together to shape smarter strategies for healthcare innovation. In this episode, you'll learn: Why patient-centered thinking belongs at the core of investment strategy. Common mistakes healthcare startups make when pitching to investors—and how to avoid them. The critical role of clinical data, mission alignment, and timing in building sustainable biotech companies. Tune in to learn how to navigate healthcare investments with purpose and ensure your biotech mission makes a lasting impact. Links: Connect with Sam Libby, and check out TCB Capital Advisors. Connect with James Zanewicz, JD, LLM, RTTP and learn about Tulane Medicine Business Development and the School of Medicine. Learn more about Clairity and Informuta. Listen to our previous episode on Drug Pricing and Accessibility. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

In the latest episode of the Health Matters podcast, former Food and Drug Administration Commissioner Scott Gottlieb joins WPP’s Wendy Lund, GCI Health’s Ryan Kuresman and Burson’s Judy Stecker to discuss the forces reshaping U.S. health policy. Gottlieb warns that while new laws such as the Inflation Reduction Act may lower government spending on drugs, consumers are unlikely to see significant relief at the pharmacy counter. Insurers’ tighter formularies and higher cost-sharing requirements, he said, could continue to drive affordability challenges for patients. The discussion also covers the future of direct-to-consumer advertising, FDA’s role in combating health misinformation and the promise of cell and gene therapies. Gottlieb shares both caution and optimism — noting the risk of consumer frustration if policy changes fail to deliver savings, while pointing to breakthroughs that are transforming treatment and outcomes. To hear his full take on the challenges and opportunities facing health care leaders, listen to the full Health Matters episode.See omnystudio.com/listener for privacy information.

Howard Gleckman, a senior fellow at the Urban Institute and Forbes columnist, provided a comprehensive overview of recent public policy changes affecting older adults. Drawing from his expertise in aging and tax policy—stemmed from personal caregiving experiences—Gleckman analyzed the implications of the Trump administration's "big beautiful bill" and related executive actions as of August 2025. The focus was on Medicaid and Medicare reforms, which could reshape long-term care, costs, and access for millions of seniors and people with disabilities.Medicaid, which supports about 7.2 million seniors and 4.8 million younger disabled individuals (dual eligibles), faces a $1 trillion reduction in federal spending over the next decade. Key changes include:Work Requirements and Paperwork: Starting potentially in December 2026, states must impose work mandates, though older adults and those with disabilities are exempt. Family caregivers' status remains unclear, risking benefit loss for those quitting jobs to provide care. Recertification is now required at least twice yearly, increasing administrative burdens and potentially deterring eligible recipients.Funding Reductions: Limits on state provider taxes (e.g., on nursing homes) will cut federal contributions by about $120 billion starting in 2028. Expansion states under the Affordable Care Act lose extra funding from January 2026, forcing tough choices: cut benefits, limit eligibility, or raise taxes. Gleckman warned that optional home and community-based services (HCBS) are most vulnerable, as nursing home care remains mandatory. While the bill allows states to expand HCBS for less needy individuals without lengthening waitlists, funding cuts make this unlikely.Staffing and Workforce Impacts: The bill repeals Biden-era minimum staffing rules for nursing homes until 2034. Combined with mass deportations, this exacerbates shortages of direct care workers, driving up costs for facilities and families.Gleckman emphasized that states may prioritize institutional care over community-based options, potentially worsening outcomes for older adults preferring to age at home.Despite campaign promises to protect Medicare, changes aim to curb fraud, boost efficiency, and emphasize prevention—but at the risk of higher costs and reduced access:Prior Authorization Expansion: For the first time, traditional fee-for-service Medicare will require prior approval for 17 procedures (e.g., back surgeries, pain injections) in a six-state demo (New Jersey, Ohio, Oklahoma, Texas, Arizona, Washington). CMS plans to use AI for reviews, with human oversight.Payment Adjustments: Skilled nursing facilities see a 2.8% payment increase for 2026, deemed insufficient by the industry. Home health agencies face a 6.4% cut ($1 billion+), sparking bipartisan opposition. The Labor Department repealed Obama-era rules, allowing home care workers to earn below federal minimum wage ($7.25/hour) and exempting them from overtime, per state laws.Enrollment and Programs: Easier enrollment in Medicare Savings Programs (for low-income beneficiaries) is delayed until 2034. The GUIDE program for dementia care navigation continues but with penalties if it fails to improve outcomes or save money. Value-based care is expanding, rewarding providers for quality over volume.Drug Pricing and Hospice: Trump favors "most favored nation" pricing to align U.S. drug costs with foreign markets, potentially supplementing Biden's negotiations. Hospice faces crackdowns on alleged fraud, though details are pending.Gleckman noted deregulation of nursing homes (e.g., rolling back transparency rules) and potential reductions in Medicare Advantage supplemental benefits like gym memberships due to insurer financial pressures.

This episode features Paige Twenter, Assistant Editor at Becker's Hospital Review, as she discusses key healthcare policy developments including restrictions on gender-affirming care, federal pressure on pharmaceutical companies to lower U.S. drug prices, and major changes to the 340B drug pricing program.

In this episode, MM+M Pharma Editor Lecia Bushak sits down with Noom's CEO Geoff Cook and Chief Medical Officer Dr. Jeffrey Egler to discuss the launch of their new Microdose GLP-1 program, designed to help people lose weight with smaller doses of the popular obesity drugs. They delve into the benefits of “micro-dosing” GLP-1s and the behavioral health components of Noom's model that aims to support long-term weight loss. Egler and Cook break down the challenges of drug pricing and accessibility, as well as the future of the obesity market. Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music.

Send us a textSchedule an Rx AssessmentSubscribe to Master The MarginH.R. 4317, PBM transparency and Medicare drug pricing...The legislative landscape is shifting fast, and if pharmacy owners want a sustainable future, advocacy can't be optional.So where do things stand and what's next?In this episode of The Bottom Line Pharmacy Podcast, Scotty Sykes, CPA, CFP®, and Bonnie Bond, CPA, sit down with B. Douglas Hoey, CEO of the NCPA, to discuss:- What the PBM Reform Act means for pharmacy reimbursement- How Medicare drug pricing changes will impact your margins- Why advocacy doesn't stop after a legislative winAnd more!More About Our Guest:Douglas Hoey is the Chief Executive Officer of the National Community Pharmacists Association. NCPA represents the owners of nearly 20,000 pharmacy small businesses who's pharmacists provide prescription dispensing services and help fill primary care gaps. The majority of these pharmacies are located in areas the CDC ranks as “high” or “very high” on the Socially Vulnerable Index. Consumers consistently rank community pharmacies as the top-rated pharmacies in the country. Hoey is a licensed pharmacist in Oklahoma, Virginia, and Texas and practiced in community pharmacies including his family's pharmacy before coming to NCPA. He is widely quoted by media as an industry expert on community pharmacy payment and practice issues. Hoey also developed and taught pharmacology courses at George Washington and Marymount universities. He is President of the World Pharmacy Council, co-Chairman of the Board of Directors for Surescripts, Chairman of the NCPA Innovation Center, and co-Chairman of the CPESN-USA Board. His pharmacy degree is from the University of Oklahoma and his MBA is from the Oklahoma City University. Learn more about Doug and the NCPA:Doug Hoey LinkedInNCPA FacebookNCPA InstagramNCPA LinkedInNCPA YouTubeNCPA Twitter (X)NCPA WebsiteStay connected with us:FacebookTwitterLinkedInScotty Sykes – CPA, CFP LinkedInScotty Sykes – CPA, CFP TwitterMore Resources on these Topics:Podcast – The One Big, Beautiful BillPodcast - Momentum on the Hill: Protecting Independent Pharmacies Through AdvocacyPodcast - The Trusted Pharmacist: Advocacy and Building a Resilient Pharmacy

What happens when patients can't afford the medicine you've worked so hard to create? In this episode, host Elaine Hamm, PhD, sits down with Vinay Patel, PharmD—Chief Pharmacy Officer at Proactive MD and Founder of MakoRx—to unpack the hidden complexities behind drug pricing, access, and affordability. Together, they explore how traditional insurance models impact patient care, and what drug developers and startups need to know to ensure their therapeutics actually reach the people who need them. In this episode, you'll discover: Why pharmacy benefit managers (PBMs) influence drug access—and what that means for your commercialization strategy. How cost-plus pricing models are changing the healthcare landscape. Key considerations for biotech innovators to ensure affordability, patient access, and long-term success. Whether you're developing a new therapeutic or trying to understand the real-world implications of drug pricing, this conversation offers a powerful look behind the pharmacy counter. Links: Connect with Vinay Patel, PharmD, and check out Proactive MD and MakoRx. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Learn more about The Study, Elaine's wine bar. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Join the Federalist Society for a webinar on the ongoing legal challenges to the Biden-era Medicare Drug Price Negotiation Program, a component of the Inflation Reduction Act. Ashley Parrish, Partner at King & Spalding, will provide an analysis of the multi-faceted litigation. He will explore how pharmaceutical companies are arguing that the program prevents accountability by granting the government "unlimited, unreviewable, unchecked rulemaking authority" over drug prices, and that it compels speech by forcing participation in agreements that imply voluntary negotiation. Mr. Parrish will also examine recent appellate court rulings and forecast the program's future, including its implications for the broader healthcare landscape. Featuring: Ashley C. Parrish, Partner, King & Spalding, LLP

For a more than a century, the Food and Drug Administration has worked to protect public health. In his research, Harvard University physician-researcher Jerry Avorn has examined how the FDA's once-rigorous gold standard approval process has been affected by a powerful shortcut known as the Accelerated Approval Program—originally designed for desperate AIDS and cancer patients. He says that change in the 1990s has allowed more than half of all new drugs onto the market before drug companies have proven they actually help people.In his new book Rethinking Medications: Truth, Power and the Drugs We Take, Avorn cites numerous examples: from a cold medicine that doesn't de-congest to billion-dollar cancer treatments that only shrink lab results to the controversial Alzheimer's drug Aduhelm—approved despite no clear cognitive benefits. In this episode, Avorn explores whether some prescriptions in your medicine cabinet are safe, effective and worth the money.

Welcome back to Impact Theory with Tom Bilyeu! In this episode, Tom and Producer Drew dive into a dynamic conversation covering everything from unexpected dinner stories with hip-hop legends and comic creators to deep reflections on global politics, commerce, and the future of technology. Tom and Drew break down Trump's recent deals, cultural realism in foreign policy, the impact of commerce as a global connector, and the blurred lines between healthy capitalism and exploitative systems. SHOWNOTES 00:00 Middle East's Self-Led Transformation 07:39 Cultural Collisions and Misguided Interventions 31:44 Eugenics: Dark Historical Perception 44:36 "Trump's Strategic Move on Drug Pricing" 01:01:45 "Reforming Loan Structures & School Funding" 01:23:07 "Critique of Money Printing Policies" 01:35:17 "Understanding Manipulation in Economics" CHECK OUT OUR SPONSORS Vital Proteins: Get 20% off by going to ⁠https://www.vitalproteins.com⁠ and entering promo code IMPACT at check out Allio Capital: Macro investing for people who want to understand the big picture. Download their app in the App Store or at Google Play, or text my name “TOM” to 511511. ButcherBox: New users that sign up for ButcherBox will receive their choice between steak tips, salmon, or chicken breast in every box for a year + $20 off their first box at ⁠https://butcherbox.com/impact⁠ Monarch Money: Use code THEORY at ⁠https://monarchmoney.com⁠ for 50% off your first year! CashApp: Download Cash App Today:⁠ https://capl.onelink.me/vFut/v6nymgjl⁠ #CashAppPod iRestore:Give yourself the gift of hair confidence this year. For a limited time only, our community is getting a HUGE discount on the iRestore Elite when you use code IMPACT at ⁠https://irestore.com⁠ iTrust Capital: Use code IMPACTGO when you sign up and fund your account to get a $100 bonus at ⁠https://www.itrustcapital.com/tombilyeu⁠  Jerry: Stop needlessly overpaying for car insurance - download the Jerry app or head to ⁠https://jerry.ai/impact⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

About this episode: This week, President Trump signed an Executive Order aimed at lowering prescription drug costs. In this episode: a look at why the U.S. spends three to four times more for drugs than many peer countries, its current approach to drug pricing policy, the directives laid out in the Executive Order, and how other countries negotiate their prices. Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University. Guest: Dr. Gerard Anderson is an expert in health policy and a professor in Health Policy and Management and International Health at the Johns Hopkins Bloomberg School of Public Health. Host: Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs at the Johns Hopkins Bloomberg School of Public Health. Show links and related content: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients—Executive Order, The White House The Potential Impacts of Cuts to Medicaid—Public Health On Call (March 2025) What's Next For Prescription Drug Pricing?—Public Health On Call (February 2023) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed

Drug Pricing; China; Budget; Trump in ME; Houthis; S. African Refugees; Milei | Yaron Brook Show

Stocks surging across the board after the U.S. and China agreed to temporarily slash tariffs. The sectors and stocks seeing the biggest moves, and what the news means for the Fed's rate policy. Plus Drugmakers on the clock, as President Trump signs an executive order aimed at lowering prescription drug cots. How the pharma space is reacting, and why one top health care analyst isn't too worried about the policy changes.Fast Money Disclaimer

In this episode of Good Morning Liberty, hosts Nate Thurston and Charles 'Chuck' Carhartt Thompson discuss a range of hot topics starting with Trump's alleged new trade deal with China. They delve into the details, criticizing the lack of real concessions and Trump's claims of a 'total reset' in tariffs. The duo also talks about Trump's new executive order on reducing prescription drug costs, exploring the implications of a 'Most Favored Nation' policy and potential pitfalls including medication shortages and economic ramifications. Alongside these big-ticket items, the episode also touches on various weekend updates including a $400 million plane gift to the Department of Defense, a discussion on habeas corpus, ICE activities, and more. Join Nate and Chuck as they provide their unique Libertarian perspective on current events. (03:50) China Trade Deal Analysis (09:28) Trump's Executive Order on Prescription Drugs (25:16) Adjustments for Unhealthy America (25:37) Government's Role in Drug Pricing (27:04) Global Price Disparities (29:35) Pharmacy Benefit Managers and Market Inefficiencies (30:48) Direct-to-Consumer Sales and Mark Cuban's Initiative (31:52) Generic vs. Name Brand Medications (32:57) Trump's Most Favored Nation Policy (38:57) Potential Consequences of Price Controls (43:26) Free Market Solutions and Government Regulation (46:48) Conclusion and Final Thoughts   Links:   https://gml.bio.link/   YOUTUBE:   https://bit.ly/3UwsRiv   RUMBLE:   https://rumble.com/c/GML   Check out Martens Minute!   https://martensminute.podbean.com/   Follow Josh Martens on X:   https://twitter.com/joshmartens13   Join the private discord & chat during the show!   joingml.com   Bank on Yourself bankonyourself.com/gml   Get FACTOR Today! FACTORMEALS.com/factorpodcast     Good Morning Liberty is sponsored by BetterHelp! Rediscover your curiosity today by visiting Betterhelp.com/GML (Get 10% off your first month)     Protect your privacy and unlock the full potential of your streaming services with ExpressVPN. Get 3 more months absolutely FREE by using our link EXPRESSVPN.com/GML